Company Overview of AnaptysBio, Inc.
AnaptysBio, Inc., an antibody development company, engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the Unites states. It is developing ANB020, a pro-inflammatory cytokine antibody that inhibits the activity of interleukin-33; and ANB019, an antibody that inhibits the function of the interleukin-36-receptor. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.
10421 Pacific Center Court
San Diego, CA 92121
Founded in 2005
Key Executives for AnaptysBio, Inc.
Chief Executive Officer, President and Director
Head of Project Management
Chief Development Officer
Compensation as of Fiscal Year 2016.
AnaptysBio, Inc. Key Developments
AnaptysBio, Inc. Initiates Multiple Ascending Dose Cohorts in ANB020 Phase 1 Clinical Trial
Jul 6 16
AnaptysBio, Inc. announced the initiation of multiple ascending dose cohorts in an on-going double-blind, placebo-controlled healthy volunteer Phase 1 study of its proprietary anti-interleukin-33 antibody (ANB020). During an earlier segment of the aforementioned Phase 1 study, AnaptysBio conducted safety, tolerability, pharmacokinetic and pharmacodynamic assessment of ANB020 in healthy volunteer cohorts administered with single doses of the antibody. Data generated from single dose cohorts was reviewed by regulatory authorities in Australia prior to the initiation of multiple ascending dose testing. ANB020 is a potent inhibitor of interleukin-33 (IL-33) developed by AnaptysBio using its proprietary SHM-XEL antibody discovery platform. IL-33 is a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. Since ANB020 acts upstream of IL-4, IL-5 and IL-13, AnaptysBio believes ANB020's IL-33 inhibitory mechanism has potential advantages in human therapy over agents that block only a subset of the cytokines responsible for atopic diseases. In addition, published human genetic analyses have linked down-modulation of IL-33 signaling with protection from asthma. AnaptysBio plans to conduct future clinical development of ANB020 in patients with atopic dermatitis, peanut allergy and asthma.
AnaptysBio, Inc. Appoints Matthew Moyle as Chief Scientific Officer
Apr 18 16
AnaptysBio, In. announced the appointment of Matthew Moyle, Ph.D. as Chief Scientific Officer. Dr. Moyle will be responsible for the discovery and early development of therapeutic antibodies generated using AnaptysBio's proprietary SHM-XEL platform. Most recently, Dr. Moyle served as Vice President of Biotherapeutics at Boehringer Ingelheim Pharmaceuticals, Inc. where he chaired Boehringer Ingelheim's International NBE Council.
AnaptysBio, Inc. Announces First-In-Human Dosing of Anti-IL-33 Antibody
Mar 10 16
AnaptysBio, Inc. announced first-in-human dosing of its proprietary anti-IL-33 antibody (ANB020) in a Phase I clinical trial. The double-blind, placebo-controlled single and multiple ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ANB020 in healthy volunteers. Interleukin-33, or IL-33, is a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. IL-33 acts on white blood cell types that subsequently release atopic disease-mediating cytokines such as IL-5, IL-13 and IL-4. Since ANB020 potently inhibits IL-33 function, and acts upstream broadly across the key cell types involved in atopy, AnaptysBio believes its mechanism has potential advantages in human therapy over agents that block only a subset of the cytokines responsible for atopic diseases. The role of IL-33 signaling in asthma has been genetically validated through human studies published in the medical literature. Subsequent to the completion of this Phase I study, AnaptysBio plans to continue clinical development of ANB020 in patients with atopic dermatitis, peanut allergy and asthma.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|